182 related articles for article (PubMed ID: 22272218)
1. Development of manganese-based nanoparticles as contrast probes for magnetic resonance imaging.
Zhen Z; Xie J
Theranostics; 2012; 2(1):45-54. PubMed ID: 22272218
[TBL] [Abstract][Full Text] [Related]
2. Revisiting an old friend: manganese-based MRI contrast agents.
Pan D; Caruthers SD; Senpan A; Schmieder AH; Wickline SA; Lanza GM
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2011; 3(2):162-73. PubMed ID: 20860051
[TBL] [Abstract][Full Text] [Related]
3. Gadolinium-based bimodal probes to enhance T1-Weighted magnetic resonance/optical imaging.
Yang CT; Hattiholi A; Selvan ST; Yan SX; Fang WW; Chandrasekharan P; Koteswaraiah P; Herold CJ; Gulyás B; Aw SE; He T; Ng DCE; Padmanabhan P
Acta Biomater; 2020 Jul; 110():15-36. PubMed ID: 32335310
[TBL] [Abstract][Full Text] [Related]
4. Paramagnetic and Superparamagnetic Inorganic Nanoparticles for T1-Weighted Magnetic Resonance Imaging.
Zeng L; Wu D; Zou R; Chen T; Zhang J; Wu A
Curr Med Chem; 2018; 25(25):2970-2986. PubMed ID: 28292235
[TBL] [Abstract][Full Text] [Related]
5. Manganese-based MRI contrast agents: past, present and future.
Pan D; Schmieder AH; Wickline SA; Lanza GM
Tetrahedron; 2011 Nov; 67(44):8431-8444. PubMed ID: 22043109
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticles in magnetic resonance imaging: from simple to dual contrast agents.
Estelrich J; Sánchez-Martín MJ; Busquets MA
Int J Nanomedicine; 2015; 10():1727-41. PubMed ID: 25834422
[TBL] [Abstract][Full Text] [Related]
7. Manganese-loaded lipid-micellar theranostics for simultaneous drug and gene delivery to lungs.
Howell M; Mallela J; Wang C; Ravi S; Dixit S; Garapati U; Mohapatra S
J Control Release; 2013 Apr; 167(2):210-8. PubMed ID: 23395689
[TBL] [Abstract][Full Text] [Related]
8. Nanotemplate-engineered nanoparticles containing gadolinium for magnetic resonance imaging of tumors.
Zhu D; Lu X; Hardy PA; Leggas M; Jay M
Invest Radiol; 2008 Feb; 43(2):129-40. PubMed ID: 18197065
[TBL] [Abstract][Full Text] [Related]
9. Integration of gadolinium in nanostructure for contrast enhanced-magnetic resonance imaging.
Marasini R; Thanh Nguyen TD; Aryal S
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jan; 12(1):e1580. PubMed ID: 31486295
[TBL] [Abstract][Full Text] [Related]
10. Fabrication and evaluation of tumor-targeted positive MRI contrast agent based on ultrasmall MnO nanoparticles.
Huang H; Yue T; Xu K; Golzarian J; Yu J; Huang J
Colloids Surf B Biointerfaces; 2015 Jul; 131():148-54. PubMed ID: 25982318
[TBL] [Abstract][Full Text] [Related]
11. Activatable 19F MRI nanoparticle probes for the detection of reducing environments.
Nakamura T; Matsushita H; Sugihara F; Yoshioka Y; Mizukami S; Kikuchi K
Angew Chem Int Ed Engl; 2015 Jan; 54(3):1007-10. PubMed ID: 25413833
[TBL] [Abstract][Full Text] [Related]
12. Structure-property relationships in manganese oxide--mesoporous silica nanoparticles used for T1-weighted MRI and simultaneous anti-cancer drug delivery.
Chen Y; Chen H; Zhang S; Chen F; Sun S; He Q; Ma M; Wang X; Wu H; Zhang L; Zhang L; Shi J
Biomaterials; 2012 Mar; 33(7):2388-98. PubMed ID: 22177841
[TBL] [Abstract][Full Text] [Related]
13. Biocompatible nanotemplate-engineered nanoparticles containing gadolinium: stability and relaxivity of a potential MRI contrast agent.
Zhu D; White RD; Hardy PA; Weerapreeyakul N; Sutthanut K; Jay M
J Nanosci Nanotechnol; 2006 Apr; 6(4):996-1003. PubMed ID: 16736756
[TBL] [Abstract][Full Text] [Related]
14. Intrinsically Zirconium-89-Labeled Manganese Oxide Nanoparticles for
Zhan Y; Ehlerding EB; Shi S; Graves SA; Goel S; Engle JW; Liang J; Cai W
J Biomed Nanotechnol; 2018 May; 14(5):900-909. PubMed ID: 29883560
[TBL] [Abstract][Full Text] [Related]
15. Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?
Neuwelt EA; Hamilton BE; Varallyay CG; Rooney WR; Edelman RD; Jacobs PM; Watnick SG
Kidney Int; 2009 Mar; 75(5):465-74. PubMed ID: 18843256
[TBL] [Abstract][Full Text] [Related]
16. Development of Gd(III) porphyrin-conjugated chitosan nanoparticles as contrast agents for magnetic resonance imaging.
Jahanbin T; Sauriat-Dorizon H; Spearman P; Benderbous S; Korri-Youssoufi H
Mater Sci Eng C Mater Biol Appl; 2015; 52():325-32. PubMed ID: 25953574
[TBL] [Abstract][Full Text] [Related]
17. Gadolinium-conjugated PLA-PEG nanoparticles as liver targeted molecular MRI contrast agent.
Chen Z; Yu D; Liu C; Yang X; Zhang N; Ma C; Song J; Lu Z
J Drug Target; 2011 Sep; 19(8):657-65. PubMed ID: 21091273
[TBL] [Abstract][Full Text] [Related]
18. Targeted Molecular Iron Oxide Contrast Agents for Imaging Atherosclerotic Plaque.
Evans RJ; Lavin B; Phinikaridou A; Chooi KY; Mohri Z; Wong E; Boyle JJ; Krams R; Botnar R; Long NJ
Nanotheranostics; 2020; 4(4):184-194. PubMed ID: 32637296
[No Abstract] [Full Text] [Related]
19. Novel Gd nanoparticles enhance vascular contrast for high-resolution magnetic resonance imaging.
Bui T; Stevenson J; Hoekman J; Zhang S; Maravilla K; Ho RJ
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20927340
[TBL] [Abstract][Full Text] [Related]
20. Gd-hydroxypyridinone (HOPO)-based high-relaxivity magnetic resonance imaging (MRI) contrast agents.
Datta A; Raymond KN
Acc Chem Res; 2009 Jul; 42(7):938-47. PubMed ID: 19505089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
